Atrium Therapeutics (RNA): T. Rowe Price Associates, Inc. cut its RNA stake below 5% (3.7%) 3.7%
T. Rowe Price Associates, Inc. cut its RNA stake below 5% (3.7%).
- 3.7%
- Stake
- 640K
- Shares owned
- Stake as of
- Sep 30, 2026
- Filed
- Nov 16, 2026
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
What came next
- Oct 7, 2026Company filing · Form 8-K · Material agreement, Unregistered sharesSigned an important agreement, and sold new shares without registering them (and 1 more item)
- Nov 12, 2026Company filing · Form 8-K · ResultsReported its results
- Nov 16, 20265% stakeT. Rowe Price Associates, Inc. reported a passive stake (13G) of 3.7%
How to read SEC Schedule 13G
A Schedule 13D and a Schedule 13G both disclose beneficial ownership of more than 5% of a US company's voting shares. A 13D is the long form, filed by holders who may seek to influence or control the company, and it must state what they intend to do. A 13G is the short form, open only to passive holders and to certain institutions holding in the ordinary course of business, and it asks no question about intent.
Full guide: Schedule 13D vs Schedule 13G: what is the difference?
What else is on file for Atrium Therapeutics
For Atrium Therapeutics, OQRO holds 1 fund holdings report (13F) dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its RNA page.
How this filing works
Explore the data
Common questions
What does this filing report about Atrium Therapeutics (RNA) stock?
T. Rowe Price Associates, Inc. cut its RNA stake below 5% (3.7%). Of the company, Schedule 13G (passive).
When did it happen, and when was it made public?
Stake as of: Sep 30, 2026. Filed: Nov 16, 2026.
Is this a trade made on a known date?
No. A holdings report is a picture of the portfolio on the last day of the quarter. It shows what was held on that day, not the day or the price at which anything was bought or sold.
Where does this information come from?
From the SEC Schedule 13G, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.
What else has been disclosed about Atrium Therapeutics recently?
For Atrium Therapeutics, OQRO holds 1 fund holdings report (13F) dated in the last 90 days. They are listed on the RNA page.
Does this mean RNA stock is a buy or a sell?
No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.
Is OQRO free?
Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.
Other disclosures at Atrium Therapeutics
Everything OQRO holds on this company is on its RNA page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO is free for everyone. No card, no trial
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data